![Changes in glomerular filtration rate and clinical course after sequential doses of carboplatin in children with embryonal brain tumors undergoing autologous stem cell transplantation | Journal of the Egyptian National Cancer Institute Changes in glomerular filtration rate and clinical course after sequential doses of carboplatin in children with embryonal brain tumors undergoing autologous stem cell transplantation | Journal of the Egyptian National Cancer Institute](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs43046-020-00024-6/MediaObjects/43046_2020_24_Fig1_HTML.png)
Changes in glomerular filtration rate and clinical course after sequential doses of carboplatin in children with embryonal brain tumors undergoing autologous stem cell transplantation | Journal of the Egyptian National Cancer Institute
![Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin | Journal of Clinical Oncology Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/1999/jco.1999.17.1.17.issue-1/jco.1999.17.1.409/20161108/images/medium/0409e001.jpeg)
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin | Journal of Clinical Oncology
![Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review | Semantic Scholar Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1bcfdfb6a0fd7f6728b02d83649beaa6bfe37c20/2-Table1-1.png)
Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review | Semantic Scholar
![Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom - Barnett - 2021 - British Journal of Clinical Pharmacology - Wiley Online Library Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom - Barnett - 2021 - British Journal of Clinical Pharmacology - Wiley Online Library](https://bpspubs.onlinelibrary.wiley.com/cms/asset/1c1fcff5-b575-4a62-8717-8a293eeca62b/bcp14419-fig-0001-m.jpg)
Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom - Barnett - 2021 - British Journal of Clinical Pharmacology - Wiley Online Library
![Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial - The Lancet Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial - The Lancet](https://www.thelancet.com/cms/attachment/2001002003/2003730936/gr1.gif)
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial - The Lancet
![Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP) | SpringerLink Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP) | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10549-020-05868-z/MediaObjects/10549_2020_5868_Fig1_HTML.png)
Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP) | SpringerLink
![Carboplatin dose calculations for patients with lung cancer: significant dose differences found depending on dosing equation choice | BMC Cancer | Full Text Carboplatin dose calculations for patients with lung cancer: significant dose differences found depending on dosing equation choice | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-022-09885-7/MediaObjects/12885_2022_9885_Fig1_HTML.png)
Carboplatin dose calculations for patients with lung cancer: significant dose differences found depending on dosing equation choice | BMC Cancer | Full Text
![Phase I/II study of weekly paclitaxel and carboplatin with concurrent radiation therapy in locally advanced non-small-cell lung cancer: Kansai Clinical Oncology Group T0401 Phase I/II study of weekly paclitaxel and carboplatin with concurrent radiation therapy in locally advanced non-small-cell lung cancer: Kansai Clinical Oncology Group T0401](https://www.oatext.com/img/IMM-4-300-g001.gif)
Phase I/II study of weekly paclitaxel and carboplatin with concurrent radiation therapy in locally advanced non-small-cell lung cancer: Kansai Clinical Oncology Group T0401
![Evaluation of the Modification of Diet in Renal Disease (MDRD) and Cockcroft-Gault (C-G) formulas in the Calvert equation for Carboplatin Dosing Whitney. - ppt video online download Evaluation of the Modification of Diet in Renal Disease (MDRD) and Cockcroft-Gault (C-G) formulas in the Calvert equation for Carboplatin Dosing Whitney. - ppt video online download](https://slideplayer.com/slide/5736905/19/images/2/Background+Carboplatin+is+a+second+generation+platinum+agent.jpg)